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Summary
Vaccination programmes are implemented either as new
vaccines become available or evidence about them accu-
mulates, or in response to specific situations. In the United
Kingdom, development and implementation of the national
immunisation programme is centrally coordinated and
funded by the Department of Health on behalf of
England, Wales, Scotland and Northern Ireland.
A number of significant changes were made to the UK
immunisation schedule for 2013/2014. Three new vaccines
were introduced: intranasal influenza and oral rotavirus for
children and subcutaneous shingles for older adults.
To ensure protection against meningococcal C infection
into adulthood, there has been a change to the schedule
for meningitis C vaccination. The temporary pertussis vac-
cination programme for pregnant women, set up in
response to an increase in the number of cases of pertussis
particularly among young babies, has been extended until
further notice. Furthermore, in response to large out-
breaks of measles in south Wales and other parts of the
UK, a national measles, mumps and rubella catch-up cam-
paign specifically targeted at unvaccinated children aged
10–16 years was launched to ensure that all children and
young people have received two doses of measles, mumps
and rubella vaccine. This review describes the rationale
behind these policy changes.
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Introduction
Vaccination policy refers to a plan of action adopted
or pursued by a government in relation to vaccin-
ation. National immunisation schedules and pro-
grammes are implemented or amended based on
vaccination policy decisions. In the United
Kingdom, development and implementation of the
national immunisation programme is centrally coor-
dinated and funded by the Department of Health
(DH) on behalf of England, Wales, Scotland and
Northern Ireland. DH is advised by the Joint
Committee on Vaccination and Immunization
(JCVI), an independent expert advisory committee.
JCVI makes recommendations to DH concerning
vaccination policy and schedules, after considering
disease epidemiology, vaccine eﬃcacy, vaccine
safety and cost-eﬀectiveness of implementing a pro-
gramme. Once a new vaccine policy has been
accepted by the UK government, DH develops a stra-
tegic plan with activities, timelines, agencies and tasks
to manage the implementation of the new policy.
Depending on the policy, diﬀerent actions will be
required, ranging from simple amendment of existing
activities to a major campaign for introduction of a
new vaccine. Changes and additions to the immun-
isation programme are incorporated alongside other
vaccines wherever possible to minimise the number of
appointments needed and disruptions to patients and
services. To facilitate the process, DH manages a net-
work of ‘Immunization Coordinators’ who have local
responsibility for implementation of new policies and
eﬀective delivery of the immunisation programme.
Figure 1 shows a timeline for the introduction of
vaccines in the UK, and Table 1 outlines the complete
routine UK immunisation schedule. For the 2013/
2014 ﬁnancial year (deﬁned as running from April
2013 to March 2014) signiﬁcant changes were made
to the UK immunisation schedule. Here we describe
the changes and outline the rationale behind these
developments in vaccine policy.
Methods
Relevant literature was identiﬁed through a search of
the online databases (MEDLINE, EMBASE and the
GOV.UK online publications library) using a number
of keywords (e.g. immunisation, vaccination, rota-
virus, inﬂuenza, shingles, meningococcal C, pertussis,
measles, mumps, rubella) either alone or in combin-
ation. A range of publications was retrieved,
including research reports, editorials, letters and
books, and a subset of 30 relevant articles and text-
books was used for our reference list. Information
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and evidence have been compiled from these to pro-
vide the reader with a concise and up-to-date review
of developments in the UK vaccine policy.
New vaccines in the schedule
Rotavirus vaccine
Rotavirus is the most common cause of severe gastro-
enteritis among children under ﬁve years of age.8
In the UK, rotavirus infection is estimated to
result in 750,000 episodes of diarrhoea and 80,000
general practice (GP) consultations each year,1 with
14,300 hospital admissions in children under ﬁve
years.2
Rotarix was added to the UK immunisation
schedule from July 2013. The protective eﬃcacy
(>85%) of Rotarix against severe rotavirus gastro-
enteritis has been demonstrated in a number of
large randomised controlled trials.3 Post-licensure
studies from the United States and Europe have
demonstrated its eﬀectiveness in real-world settings,
with signiﬁcant reductions in hospital admissions for
rotavirus disease.4 Safety is a primary concern of par-
ents accepting a new vaccine that is administered to
infants to prevent disease causing high morbidity yet
very low mortality. An early rotavirus vaccine
(RotaShield) used in the US was associated with a
signiﬁcant risk of intussusception among children
who received it.5 Large pre-licensure studies showed
no association with intussusception,3 but there is evi-
dence from post-marketing surveillance that the two
current rotavirus vaccines (Rotarix and RotaTeq) are
associated with a slightly increased risk of intussus-
ception.6 However, the data suggest that the beneﬁt
from reduced cases of rotavirus gastroenteritis far
outweighs the risks.6 Nevertheless, these ﬁndings
highlight the need for continued safety monitoring
by countries introducing a rotavirus vaccine.
In November 2012, following the procurement of
Rotarix at a cost-eﬀective price, DH announced its
decision to introduce the rotavirus vaccine into the
national immunisation schedule from 2013.7 Rotarix,
a live-attenuated, orally administered two-dose vac-
cine, is recommended to be given at two and three
months of age, via GP surgeries, alongside other pri-
mary immunisations scheduled to be given at that
time (Table 1). Because of the possible link to intus-
susception, it is recommended that the ﬁrst dose is
received before 15 weeks of age and that the course
should be completed by 24 weeks of age.7
Information ﬂyers and leaﬂets for parents have been
produced to support the introduction of the rotavirus
vaccine, and a Q&A factsheet has been developed for
health professionals. These are available on the UK
government’s immunisation webpage (www.gov.uk/
government/collections/immunisation).
Preliminary ﬁndings from the ﬁrst post-vaccina-
tion year in the UK suggest 88% vaccine uptake for
a complete two-dose course, and a 67% reduction in
Figure 1. Timeline for introduction of vaccines in the UK.
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laboratory-conﬁrmed rotavirus infections compared
with the pre-vaccination 10-year average for
2000–2013.9
Influenza vaccine for children
Estimates of excess winter deaths potentially attribut-
able to inﬂuenza in the last decade in England and
Wales range from not determined (2005/2006 and
2006/2007) to 10,351 (2008/2009).10 The risk of serious
illness from inﬂuenza is highest amongst children
under six months of age, older people, those with
certain underlying health conditions and pregnant
women.7
Until recently, annual inactivated inﬂuenza vac-
cine given by intramuscular injection has been oﬀered
to individuals 65 years of age, and all those aged six
months or older in clinical risk groups (chronic renal,
heart, respiratory, liver or neurological disease; dia-
betes; immunosuppression; asplenia or dysfunction of
the spleen; pregnancy).7 In 2012, JCVI recommended
that the routine annual ﬂu immunisation programme
be extended to all children aged 2–16 years from
September 2013. It is expected to appreciably lower
Table 1. The UK routine immunisation schedule 2013/2014.
Age at which to immunise Diseases protected against Vaccines offered
2 months old Diphtheria, tetanus, pertussis, polio, Haemophilus
influenzae type b (Hib)
Pneumococcal disease
Rotavirus
DTaP/IPV/Hib
PCV
Rotavirus
3 months old Diphtheria, tetanus, pertussis, polio, Hib
Meningococcal group C disease (MenC)
Rotavirus
DTaP/IPV/Hib
MenC
Rotavirus
4 months old Diphtheria, tetanus, pertussis, polio, Hib
Pneumococcal disease
DTaP/IPV/Hib
PCV
12–13 months old Hib/MenC
Pneumococcal disease
Measles, mumps, rubella
Hib/MenC
PCV
MMR
2–3 years old (gradually
to include all 2–16 year
olds by 2015)
Influenza (given prior to the flu season in Sept/Oct) Flu nasal spray (annual)
3 years and 4 months old Diphtheria, tetanus, pertussis, polio
Measles, mumps, rubella
dTaP/IPV or DTaP/IPV
MMR
12–13 years old (girls) Cervical cancer caused by human papillomavirus
types 16 and 18 (and genital warts caused by types
6 and 11)
HPV
Around 14 years old Tetanus, diphtheria, polio
MenC
Td/IPV
MenC
Young adult catch-up to
start 2014 (probably
for five years)
MenC (before starting higher or further education) MenC
65 years old Pneumococcal disease PPV
65 years old Influenza (given prior to the flu season in Sept/Oct) Flu injection (annual)
70 years old Shingles Shingles
From 28 weeks of pregnancy Pertussis dTaP/IPV
Source: Adapted from Public Health England.7
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the public health impact of ﬂu by directly averting a
large number of cases of disease in children, and
through lowering ﬂu transmission in the community,
indirectly preventing ﬂu in individuals at high risk of
serious illness from inﬂuenza, including unvaccinated
younger children, people in clinical risk groups and
older adults. This will substantially reduce ﬂu-related
illness, GP consultations, hospital admissions and
deaths.11 Mathematical models predict that the
long-term incidence of inﬂuenza A and inﬂuenza B
in the UK could decrease by 65–97% and 85–96%,
respectively, in the overall population by vaccinating
individuals aged 2–16 years.12 Implementing an
annual inﬂuenza immunisation programme for all
children will inevitably have an impact on workforce
capacity. As a result, full coverage of this age group
will be phased in over several seasons. For 2013/2014
the programme was rolled out to all two and three
year olds through GP, and local geographical pilots
are being conducted among older children to identify
the most eﬀective delivery method for full roll out in
2015/2016. Long-term success of extending the pro-
gramme to all children aged 2–16 years is likely to
depend on adopting a multi-professional approach
involving schools and teachers as well as healthcare
professionals.
Fluenz, a live-attenuated, intranasal inﬂuenza vac-
cine has been recommended for use in this pro-
gramme. This vaccine has been found to give
greater protection against culture-conﬁrmed and
symptomatic inﬂuenza in children than the current
inactivated inﬂuenza vaccine.13 It has a good safety
proﬁle in children aged two years and older and has
an established history of use in the US.14 A single
dose of Fluenz gives adequate protection in chil-
dren.15 Therefore, JCVI recommends that most chil-
dren should be oﬀered a single dose.7 However,
children in clinical risk groups aged two to less than
nine years who have not received inﬂuenza vaccine
before should be oﬀered two doses, given at least
four weeks apart. In a change to the previous recom-
mendations, children aged 2–17 years in clinical risk
groups will be oﬀered the intranasal vaccine rather
than the inactivated injectable inﬂuenza vaccine.
Children aged six months to less than two years in
clinical risk groups will continue to be oﬀered the
inactivated inﬂuenza vaccine.7
Extending the ﬂu immunisation programme to all
children will have the added advantage of raising
awareness of the beneﬁts of ﬂu immunisation amongst
parents. DH anticipate that as ﬂu immunisation for
children becomes accepted as routine, this will have a
positive impact on uptake rates for others who are
eligible for ﬂu immunisation, particularly those in clin-
ical risk groups for whom the risk of serious
complications is highest, and for whom coverage is
presently only around 50%.7 Parents of young chil-
dren do not always perceive inﬂuenza to be a serious
disease.16 Therefore, a challenge for policymakers and
health professionals will be to increase public aware-
ness of the potential severity of inﬂuenza.
Shingles vaccine
Shingles (herpes zoster) is a debilitating condition
caused by the reactivation of a latent varicella
zoster virus (chickenpox) infection. It occurs most
frequently and is more severe in older people.17 It is
estimated that over 50,000 people 70 years old are
aﬀected in the UK each year. Around one in 1000
people 70 years old who develop shingles die of
the infection.17
Zostavax, a vaccine to prevent shingles, was added
to the UK immunisation schedule from September
2013. Zostavax, a live-attenuated vaccine, is given
as a single dose by subcutaneous injection preferably
in the deltoid region of the upper arm. It can be given
at the same time (in a diﬀerent body part) as seasonal
inﬂuenza vaccine and at the same time as 23-valent
pneumococcal polysaccharide vaccine in eligible
patients (Table 1). It is recommended that the vaccine
be routinely oﬀered via GP surgeries, to people aged
70 years. There will also be a catch-up programme of
limited duration for those aged 79 years. The eﬃcacy
of the vaccine declines with age and so it is not rec-
ommended for people 80 years old.7 Information
leaﬂets for patients have been produced to support
the introduction of the shingles vaccine, and a fact-
sheet has been developed for health professionals.
These are available on the UK government’s immun-
isation webpage (www.gov.uk/government/collections/
immunisation).
In a clinical trial, a single dose of Zostavax was
assessed in 17,775 adults aged 70 years. The vaccine
reduced the incidence of shingles by 38%, and the
incidence of post-herpetic neuralgia by 66.8%.18
The vaccine has a good safety proﬁle, is well tolerated
and is also immunogenic in individuals who have had
a history of shingles prior to vaccination.19 The
impact of vaccination in the UK is predicted to be
11,000 fewer cases of shingles and 1500 fewer cases of
post-herpetic neuralgia each year in England and
Wales.17
Changes to the schedule
Meningococcal C vaccine
The Meningococcal C (MenC) vaccination pro-
gramme was introduced into the UK childhood
4 Journal of the Royal Society of Medicine Open 6(4)
immunisation programme in 1999 (Figure 1). Since
then, invasive meningococcal disease (IMD) caused
by meningococcal serogroup C has fallen by over
95% and cases are now at an extremely low level.7
It is estimated that 13,000 cases of disease and 1300
deaths have been prevented.20
From June 2013 signiﬁcant changes were made to
the MenC vaccination schedule based on advice from
JCVI. This included the removal of the second dose
at age four months from the routine schedule for
infants, and the introduction of an adolescent booster
dose at around 14 years of age.
The dose at four months has been removed from
the schedule on the basis of evidence that a single
dose of some varieties of MenC vaccine at three
months of age is suﬃciently immunogenic in infants
to provide protection against serogroup C meningo-
coccal disease in the ﬁrst year of life until the ﬁrst
booster at 12–13 months of age when Hib
(Haemophilus inﬂuenzae type b)/MenC vaccine is
oﬀered.21 Of the three licensed MenC conjugate vac-
cines available in the UK, Meningitec, NeisVac-C
and Menjugate Kit, only NeisVac-C and Menjugate
Kit are suitable as a single dose for infants.21
Additionally, recent evidence shows that immunity
conferred by MenC immunisation in early childhood
provides a short-term protective immune response.22
Protection given by vaccination at 12 months wanes
by the teenage years, but vaccination later in child-
hood provides higher levels of antibody that persist
for longer.23 Following consideration of the evidence,
JCVI recommended the introduction of an adolescent
booster to be given at the same time as the teenage
tetanus, diphtheria and polio vaccine (Td/IPV)
(Table 1), to extend protection into early adulthood.
From August 2014, there will also be a catch-up pro-
gramme of limited duration (probably ﬁve years) to
oﬀer the MenC vaccine to ﬁrst time university
entrants <25 years of age (i.e. those who will not
have been vaccinated under the revised schedule at
around age 14 years).
Pertussis vaccine in pregnancy
Before the introduction of pertussis immunisation in
the 1950s, the average annual number of notiﬁcations
exceeded 120,000 in the UK.7 Severe complications
and deaths occur most commonly in infants under six
months of age.
A temporary pertussis vaccination programme for
pregnant women was introduced in October 2012 in
response to a signiﬁcant rise in the number of pertus-
sis cases across the UK.24 The highest rates were in
infants aged under three months, including several
deaths among young babies.24 In May 2013, DH
announced this temporary programme was to con-
tinue until further notice following advice from
JCVI based on preliminary data on the evaluation
of the immunisation programme, including immun-
isation coverage in pregnant women and surveillance
data of the impact of the programme on disease in
infants and on the safety of the vaccine in pregnant
women. The key aim of the programme is to protect
vulnerable infants from birth in the ﬁrst months of
life, before they can be fully protected by routine
infant immunisation. DH recommends vaccination
of pregnant women between 28 and 38 weeks’ gesta-
tion.7 Immunisation of women in the later stages of
pregnancy has been shown to boost pertussis antibo-
dies, which may then be passed from mother to baby
and so protect the infant until given the vaccine at
two months of age.24 Pertussis vaccine is only avail-
able in combination with other vaccines (diphtheria,
tetanus, polio) and DH advises that the combination
vaccine Repevax (diphtheria, tetanus, pertussis and
polio vaccine (dTaP/IPV)) be used as a pertussis
booster in pregnant women.7 A challenge anticipated
for this programme was the possible reluctance
among pregnant women to receive a vaccine, as this
is contrary to the usual advice about avoiding medi-
cation in pregnancy. Indeed, the average monthly
pertussis vaccine coverage for pregnant women
between October 2012 and September 2013 was
only 53.9%.25 However, there is no evidence of risk
from vaccinating pregnant women with inactivated
viral or bacterial vaccines or toxoids such as those
included in Repevax.7 Information ﬂyers and leaﬂets
for pregnant women and health professionals have
been produced to communicate this message.
The pertussis immunisation in pregnancy pro-
gramme in England has shown high levels of protec-
tion against pertussis in babies born to vaccinated
mothers.26 For the ﬁrst nine months of 2013 com-
pared with the same period in 2012, there was a
78% reduction in conﬁrmed cases and a 68% fall in
hospitalisations in infants younger than three
months.26
Catch-up campaigns
Measles, mumps and rubella vaccine
In 1998, the Lancet published a study by Wakeﬁeld
et al. of a small case series of children with autism
suggesting a link with measles, mumps and rubella
vaccine (MMR).27 This attracted considerable nega-
tive publicity for MMR in the mainstream media,
and despite good scientiﬁc evidence against such an
association,28 adverse media coverage was sustained
over the next few years. Although the Wakeﬁeld
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paper was eventually discredited and retracted by the
Lancet,29 the impact was a dramatic reduction in
MMR vaccine coverage.30 Whilst uptake of MMR
vaccine has now improved markedly, large numbers
of unvaccinated children in the cohorts most aﬀected
by the decline in coverage have reached their teenage
years, when the risk of transmission increases. In
April 2013, in response to large outbreaks of measles
in south Wales and other parts of the UK, DH
announced a national MMR catch-up campaign.
The campaign speciﬁcally targeted unvaccinated chil-
dren aged 10–16 years with the aim of protecting
them and preventing further outbreaks in secondary
schools, and therefore onward transmission to young
infants and other vulnerable groups. The strategy
included raising demand through targeted communi-
cations, identiﬁcation of unvaccinated children
through primary care and child health registers and
provision of vaccination in primary care or other set-
tings such as schools. By August 2013, approximately
60,000 previously unvaccinated 10–16 year olds had
received one dose of MMR and the number of mea-
sles cases was falling.20
Discussion
Immunisation is the most important way of protect-
ing individuals and the population from vaccine pre-
ventable infectious diseases. The UK immunisation
schedule is continuously being reviewed and revised
as new vaccines become available, in response to spe-
ciﬁc outbreaks or as evidence accumulates about their
impact. For all vaccine-preventable infections in the
UK, enhanced national surveillance is in place to
monitor vaccine coverage, the impact of the vaccin-
ation programmes on burden of disease and vaccine
safety.
Communication is the key to successful implemen-
tation of a new vaccine policy, in particular to allay
public fears and mitigate potential media scares.
Multiple routes are employed so that health profes-
sionals and the public understand the change and the
actions that they need to take to facilitate its imple-
mentation. Health professionals can keep up to date
with UK immunisation changes and the rationale
behind them by consulting the online version of
the Green Book7 and other resources available on
the UK government’s immunisation webpage
(www.gov.uk/government/collections/immunisation).
For the public, promotional resources include: leaf-
lets; fact sheets; press, television, and radio advertise-
ments; videos and Internet materials, including
‘Q and A’ formats and frequently asked questions
(FAQs). A multi-professional approach involving
policymakers, healthcare professionals as well as
schools and teachers for child and adolescent sched-
ules, is vital for the success of vaccination pro-
grammes in the UK. It is especially important that
they remain enthusiastic and committed to delivering
a high-quality immunisation service through ongoing
changes in organisational and operational structures
set out in the recent national health reforms imple-
mented from April 2013.
Declarations
Competing interests: None declared
Funding: None declared
Ethical approval: Not applicable
Guarantor: CA
Contributorship: CA conceptualised and designed the review
paper. CA and SH reviewed the literature. CA drafted the initial
manuscript, and CA and SH approved the ﬁnal manuscript as
submitted.
Acknowledgements: None
Provenance: Not commissioned; Bayad Abdalrahman and
Emilie Karaﬁllakis
References
1. TamCC,RodriguesLC,VivianiL, et al. Longitudinal study
of infectious intestinal disease in the UK (IID2 study): inci-
dence in the community and presenting to general practice.
Gut 2012; 61: 69–77. doi: 10.1136/gut.2011.238386.
2. Harris JP, Jit M, Cooper D and Edmunds WJ.
Evaluating rotavirus vaccination in England and
Wales. Part I. Estimating the burden of disease.
Vaccine 2007; 25: 3962–3970.
3. Soares-Weiser K, Maclehose H, Bergman H, et al.
Vaccines for preventing rotavirus diarrhoea: vaccines
in use. Cochrane Database Syst Rev 2012; 11:
CD008521. doi: 10.1002/14651858.CD008521.pub3.
4. Lopman BA, Payne DC, Tate JE, Patel MM, Cortese
MM and Parashar UD. Post-licensure experience with
rotavirus vaccination in high and middle income coun-
tries; 2006 to 2011. Curr Opin Virol 2012; 2: 434–442.
doi: 10.1016/j.coviro.2012.05.002.
5. Schwartz JL. The first rotavirus vaccine and the politics
of acceptable risk. Milbank Q 2012; 90: 278–310. doi:
10.1111/j.468-0009.2012.00664.x.
6. Desai R, Cortese MM, Meltzer MI, et al. Potential
intussusception risk versus benefits of rotavirus vaccin-
ation in the United States. Pediatr Infect Dis J 2013; 32:
1–7. doi: 10.1097/INF.0b013e318270362c.
7. Department of Health. Immunisation against infectious
disease. The Green Book, https://www.gov.uk/govern-
ment/collections/immunisation-against-infectious-dis-
ease-the-green-book (2013, accessed 28 March 2014).
8. Jit M, Pebody R, Chen M, Andrews N and Edmunds
WJ. Estimating the number of deaths with rotavirus as a
cause in England and wales. Hum Vaccin 2007; 3: 23–26.
6 Journal of the Royal Society of Medicine Open 6(4)
9. Atchison C, Collins S, Brown D, Ramsay ME and
Ladhani S. Reduction in rotavirus disease due to the
infant immunisation programme in England; evidence
from national surveillance. J Infect 2015; 20(15): 00028–6.
10. Donaldson LJ, Rutter PD, Ellis BM, et al. English mor-
tality from A/H1N1. Comparisons with recent flu mortal-
ity. BMJ 2010; 340: c612. doi: 10.1136/bmj.c612.
11. Pitman RJ, Nagy LD and Sculpher MJ. Cost-effective-
ness of childhood influenza vaccination in England and
Wales: results from a dynamic transmission model.
Vaccine 2013; 31: 927–42. doi: 10.1016/j.vaccine.
2012.12.010.
12. Vynnycky E, Pitman R, Siddiqui R, Gay N and
Edmunds WJ. Estimating the impact of childhood
influenza vaccination programmes in England and
Wales. Vaccine 2008; 26: 5321–5330. doi: 10.1016/
j.vaccine.2008.06.101.
13. Belshe RB, Edwards KM, Vesikari T, et al. Live atte-
nuated versus inactivated influenza vaccine in infants
and young children. N Engl J Med 2007; 356: 685–696.
14. Centers for Disease Control and Prevention. Safety of
influenza A (H1N1) 2009 monovalent vaccines –
United States, October 1–November 24, 2009.
MMWR Morb Mortal Wkly Rep 2009; 58: 1351–1356.
15. Bracco NH, Farhat CK, Tregnaghi MW, et al. Efficacy
and safety of 1 and 2 doses of live attenuated influenza
vaccine in vaccine-naive children. Pediatr Infect Dis J
2009; 28: 365–71. doi: 10.1097/INF.0b013e31819219b8.
16. Chantler T, Pace D, Wright A, et al. Uptake and
acceptability of influenza vaccination in day nursery
children. Community Pract 2007; 80: 32–36.
17. van Hoek AJ, Gay N, Melegaro A, Opstelten W and
Edmunds WJ. Estimating the cost-effectiveness of vac-
cination against herpes zoster in England and Wales.
Vaccine 2009; 27: 1454–1467. doi: 10.016/
j.vaccine.2008.12.024.
18. Oxman MN and Levin MJ. Vaccination against herpes
zoster and postherpetic neuralgia. J Infect Dis 2008;
197(Suppl 2): S228–S236. doi: 10.1086/522159.
19. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-
zoster virus-specific immune responses in elderly recipi-
ents of a herpes zoster vaccine. J Infect Dis 2008; 197:
825–835. doi: 10.1086/528696.
20. Donovan H and Bedford H. Immunisation: changes in
the UK for children and young people. Nurs Child
Young People 2013; 25: 16–20. doi: 10.7748/
ncyp2013.11.25.9.16.e466.
21. Findlow H, Borrow R, Andrews N, et al.
Immunogenicity of a single dose of meningococcal
group C conjugate vaccine given at 3 months of age
to healthy infants in the United Kingdom. Pediatr
Infect Dis J 2012; 31: 616–622. doi: 10.1097/
INF.0b013e31824f34e6.
22. Khatami A, Snape MD, John T, et al. Persistence of
immunity following a booster dose of Haemophilus
influenzae type B-Meningococcal serogroup C glyco-
conjugate vaccine: follow-up of a randomized con-
trolled trial. Pediatr Infect Dis J 2011; 30: 197–202.
doi: 10.1097/INF.0b013e3181f728fd.
23. de Whalley PC, Snape MD, Plested E, et al. Long-term
seroprotection after an adolescent booster meningococ-
cal serogroup C vaccination. Arch Dis Child 2013; 98:
686–691. doi: 10.1136/archdischild-2013-303893.
24. Amirthalingam G, Gupta S and Campbell H. Pertussis
immunisation and control in England and Wales, 1957
to 2012: a historical review. Euro Surveill 2013; 18(pii):
20587.
25. Public Health England. Pertussis vaccine uptake in
pregnant women October 2012 to September 2013,
https://www.gov.uk/government/publications/pertus-
sis-vaccine-uptake-in-pregnant-women-october-2012-
to-september-2013 (2013, accessed 28 March 2014).
26. Amirthalingam G, Andrews N, Campbell H, et al.
Effectiveness of maternal pertussis vaccination in
England: an observational study. Lancet 2014; 384:
1521–1528. doi: 10.016/S0140-6736(14)60686-3.
27. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-
lymphoid-nodular hyperplasia, non-specific colitis,
and pervasive developmental disorder in children.
Lancet 1998; 351: 637–641.
28. Wilson K, Mills E, Ross C, McGowan J and Jadad A.
Association of autistic spectrum disorder and the mea-
sles, mumps, and rubella vaccine: a systematic review
of current epidemiological evidence. Arch Pediatr
Adolesc Med 2003; 157: 628–634.
29. Retraction – Ileal-lymphoid-nodular hyperplasia, non-
specific colitis, and pervasive developmental disorder in
children. Lancet 2010;375:445. doi: 10.1016/S0140-
6736(10)60175-4.
30. Ramsay ME. Measles: the legacy of low vaccine cover-
age. Arch Dis Child 2013; 98: 752–724. doi: 10.1136/
archdischild-2013-304292.
Atchison and Hassounah 7
